Results 51 to 60 of about 7,352,857 (294)

Hepatic myeloid-derived suppressor cells in cancer [PDF]

Cancer Immunology, Immunotherapy, 2015
Myeloid-derived suppressor cells are key components of tumor-induced immune suppression. They are composed of a heterogeneous population of immature myeloid cells that abrogates innate and adaptive immune responses. Myeloid-derived suppressor cells accumulate not only in peripheral blood, secondary lymphoid organs and tumors, but also in the liver in ...
José, Medina-Echeverz, Tobias, Eggert, Miaojun, Han, Tim F, Greten   +3 more
openaire   +2 more sources

p140Cap inhibits β-Catenin in the breast cancer stem cell compartment instructing a protective anti-tumor immune response

Nature Communications, 2023
The p140Cap adaptor protein is a tumor suppressor in breast cancer associated with a favorable prognosis. Here we highlight a function of p140Cap in orchestrating local and systemic tumor-extrinsic events that eventually result in inhibition of the ...
Vincenzo Salemme, Mauro Vedelago, Alessandro Sarcinella, Federico Moietta, Alessio Piccolantonio, Enrico Moiso, Giorgia Centonze, Marta Manco, Andrea Guala, Alessia Lamolinara, Costanza Angelini, Alessandro Morellato, Dora Natalini, Raffaele Calogero, Danny Incarnato, Salvatore Oliviero, Laura Conti, Manuela Iezzi, Daniela Tosoni, Giovanni Bertalot, Stefano Freddi, Francesco A. Tucci, Francesco De Sanctis, Cristina Frusteri, Stefano Ugel, Vincenzo Bronte, Federica Cavallo, Paolo Provero, Marta Gai, Daniela Taverna, Emilia Turco, Salvatore Pece, Paola Defilippi   +32 more
doaj   +1 more source

Engineering peptides into antibodies—opportunities and strategies for therapeutic innovation

FEBS Letters, EarlyView.
Peptides and antibodies occupy complementary therapeutic niches. Peptides recognize difficult targets in a compact format, while antibodies add specificity, long half‐life, and effector functions. This review examines strategies that merge both modalities—peptide grafting into loops, terminal and Fc fusions, and bioconjugation—highlighting how ...
Jinling Wang, Ruslana Romaniuk, Hristo L. Svilenov   +2 more
wiley   +1 more source

Targeting of immunosuppressive myeloid cells from glioblastoma patients by modulation of size and surface charge of lipid nanocapsules

Journal of Nanobiotechnology, 2020
Background Myeloid derived suppressor cells (MDSCs) and tumor-associated macrophages (TAMs) are two of the major players involved in the inhibition of anti-tumor immune response in cancer patients, leading to poor prognosis.
Laura Pinton, Sara Magri, Elena Masetto, Marina Vettore, Ilaria Schibuola, Vincenzo Ingangi, Ilaria Marigo, Kevin Matha, Jean-Pierre Benoit, Alessandro Della Puppa, Vincenzo Bronte, Giovanna Lollo, Susanna Mandruzzato   +12 more
doaj   +1 more source

Myeloid-Derived Suppressor Cells [PDF]

, 2015
Myeloid-derived suppressor cells (MDSCs) are a heterogeneous population of immature myeloid cells that suppress innate and adaptive immunity. MDSCs are present in many disease settings; however, in cancer, they are a major obstacle for both natural antitumor immunity and immunotherapy.
Katherine H, Parker, Daniel W, Beury, Suzanne, Ostrand-Rosenberg   +2 more
openaire   +2 more sources

Metastatic niche shaped by host factors influences disseminated cancer cell fate

FEBS Letters, EarlyView.
Metastasis is shaped not only by cancer cells but also by the environments they encounter. This review explores how factors such as aging, diet, the microbiome, lifestyle, and environmental exposures remodel organ‐specific niches in the lung, liver, bone, and brain, influencing where metastatic cells survive, remain dormant, or grow, and ultimately ...
Gwennan Delyth Ward, Álvaro Ruiz‐Tabas, Patricia Altea‐Manzano   +2 more
wiley   +1 more source

Myeloid-Derived Suppressor Cells in Lung Transplantation

Frontiers in Immunology, 2019
Myeloid-derived suppressor cells (MDSC) are a heterogeneous group of immune cells from the myeloid lineage. MDSCs expand in pathological situations, such as chronic infection, cancer, autoimmunity, and allograft rejection.
Tobias Heigl, Anurag Singh, Berta Saez-Gimenez, Janne Kaes, Anke Van Herck, Annelore Sacreas, Hanne Beeckmans, Arno Vanstapel, Stijn E. Verleden, Dirk E. Van Raemdonck, Geert Verleden, Bart M. Vanaudenaerde, Dominik Hartl, Robin Vos   +13 more
doaj   +1 more source

Myeloid-derived suppressor cells and vaccination against pathogens

Frontiers in Cellular and Infection Microbiology, 2022
It is widely accepted that the immune system includes molecular and cellular components that play a role in regulating and suppressing the effector immune response in almost any process in which the immune system is involved.
Estefanía Prochetto, Eliana Borgna, Carlos Jiménez-Cortegana, Víctor Sánchez-Margalet, Gabriel Cabrera   +4 more
doaj   +1 more source

Myeloid-Derived Suppressor Cells and Mesenchymal Stem/Stromal Cells in Myeloid Malignancies [PDF]

, 2021
Myeloid malignancies arise from an altered hematopoietic stem cell and mainly comprise acute myeloid leukemia, myelodysplastic syndromes, myeloproliferative malignancies, and chronic myelomonocytic leukemia.
Kapor, Sunčica, Juan F. Santibanez, Santibanez, Juan F., Suncica Kapor   +3 more
core   +1 more source

Tumour–host interactions in Drosophila: mechanisms in the tumour micro‐ and macroenvironment

Molecular Oncology, EarlyView.
This review examines how tumour–host crosstalk takes place at multiple levels of biological organisation, from local cell competition and immune crosstalk to organism‐wide metabolic and physiological collapse. Here, we integrate findings from Drosophila melanogaster studies that reveal conserved mechanisms through which tumours hijack host systems to ...
José Teles‐Reis, Tor Erik Rusten
wiley   +1 more source